Campbell & CO Investment Adviser LLC Invests $673,000 in Takeda Pharmaceutical Co. $TAK

Campbell & CO Investment Adviser LLC acquired a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 45,981 shares of the company’s stock, valued at approximately $673,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Goldman Sachs Group Inc. grew its position in Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after acquiring an additional 692,404 shares during the last quarter. Brandes Investment Partners LP boosted its stake in shares of Takeda Pharmaceutical by 5.9% in the 2nd quarter. Brandes Investment Partners LP now owns 3,712,278 shares of the company’s stock valued at $57,392,000 after purchasing an additional 208,136 shares in the last quarter. Managed Asset Portfolios LLC grew its holdings in shares of Takeda Pharmaceutical by 1.3% during the 2nd quarter. Managed Asset Portfolios LLC now owns 1,488,843 shares of the company’s stock valued at $23,018,000 after purchasing an additional 19,177 shares during the last quarter. Bank of America Corp DE raised its position in Takeda Pharmaceutical by 225.8% in the 2nd quarter. Bank of America Corp DE now owns 1,037,163 shares of the company’s stock worth $16,035,000 after purchasing an additional 718,805 shares during the period. Finally, Quantinno Capital Management LP lifted its stake in Takeda Pharmaceutical by 54.5% in the second quarter. Quantinno Capital Management LP now owns 797,036 shares of the company’s stock worth $12,322,000 after purchasing an additional 280,992 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Down 0.0%

TAK opened at $16.16 on Wednesday. Takeda Pharmaceutical Co. has a one year low of $12.80 and a one year high of $16.48. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.37 and a quick ratio of 0.76. The business has a 50 day simple moving average of $15.02 and a two-hundred day simple moving average of $14.71. The firm has a market capitalization of $51.40 billion, a price-to-earnings ratio of 201.94 and a beta of 0.03.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.44 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.44. The firm had revenue of $7.30 billion for the quarter, compared to analyst estimates of $8.01 billion. Takeda Pharmaceutical had a return on equity of 10.32% and a net margin of 0.86%.Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. Analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on TAK. Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. Morgan Stanley began coverage on Takeda Pharmaceutical in a research report on Tuesday, January 13th. They set an “overweight” rating on the stock. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Takeda Pharmaceutical has an average rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.